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Gene 33 (Mig6, ERRFI1) is an adaptor protein with multiple
cellular functions.We recently linkedGene 33 to theDNAdam-
age response (DDR) induced by hexavalent chromium (Cr(VI)),
but themolecular mechanism remains unknown. Here we show
that ectopic expression of Gene 33 triggers DDR in an ATM
serine/threonine kinase (ATM)–dependent fashion and through
pathways dependent or not dependent on ABL proto-oncogene
1 non-receptor tyrosine kinase (c-Abl). We observed the clear
presence of Gene 33 in the nucleus and chromatin fractions of
the cell.We also found that the nuclear localization ofGene 33 is
regulated by its 14-3-3–binding domain and that the chromatin
localization of Gene 33 is partially dependent on its ErbB-bind-
ing domain. Our data further indicated that Gene 33 may regu-
late the targeting of c-Abl to chromatin. Moreover, we observed
a clear association of Gene 33 with histone H2AX and that
ectopic expressionofGene 33promotes the interactionbetween
ATM and histone H2AX without triggering DNA damage. In
summary, our results reveal nuclear functions of Gene 33 that
regulateDDR. The nuclear localization of Gene 33 also provides
a spatial explanation of the previously reported regulation of
apoptosis by Gene 33 via the c-Abl/p73 pathway. On the basis of
these findings and our previous studies, we propose that Gene
33 is a proximal regulator of DDR that promotes DNA repair.
Gene 33 is an inducible adaptor protein containing multiple
domains for protein–protein interaction and signal transduc-
tion (Fig. 1A). These include a CRIB domain for interaction
with small GTPases of the Rho family, a 14-3-3–binding
domain (14-3-3BD), several proline-rich SH33-binding domains,
an SH2-binding domain, and a PDZ-binding domain (1–5). A
region highly homologous to the non-receptor-tyrosine kinase-
activated CDC42-associated kinase 1 (ACK-1) is located at the
C-terminal half of the protein (6), within which is an ErbB-
binding domain (EBD) (7–10). There are two stretches of PEST
sequences, suggesting that Gene 33 is a potential target for pro-
teasome-mediated protein degradation (11). A putative DEAD
box is located in theN-terminal half of the protein (12). A puta-
tive nuclear localization sequence (NLS) is located close to the
C terminus of the protein (13).
Themost functionally significant domain of Gene 33 charac-
terized thus far is its EBD. EBD of Gene 33 has been well-char-
acterized to be required for binding of Gene 33 to EGFR and
c-Abl (8–10, 14). Gene 33 interacts with the kinase domain of
EGFR, thereby inhibiting its kinase activity (10). Binding of
Gene 33 to the kinase domain of c-Abl, on the other hand,
elevates its kinase activity (14). Gene 33 interacts with kinase
domains of EGFR and c-Abl through its EBD in an appar-
ently very similar fashion, as these domains are structurally
close (14). Several residues within the EBD, including Tyr-
358, are critical for its binding to EGFR and c-Abl (10, 14).
Mutation of Tyr-358 to alanine (Y358A) significantly dis-
rupts the interaction of Gene 33 with EGFR or c-Abl (Fig.
1A) (10, 14).
Gene 33 is an immediate early response protein that can be
induced by a wide array of mitogenic and stress stimuli, includ-
ing ligands for receptors of the EGFR family (9, 15–18). Thus,
Gene 33 is viewed as a feedback inhibitor of the EGFR signaling
pathway (15, 19). Accumulating evidence also indicates that
Gene 33 promotes apoptosis and senescence (14, 17, 20, 21).
The pro-apoptotic function of Gene 33 was first observed in rat
neonatal cardiomyocytes, where overexpression of Gene 33
induces dramatic apoptosis (17). Depletion of Gene 33 by RNAi
reduces apoptosis induced by acute hypoxia in part through
inhibition of the EGFR-mediated activation of the pro-survival
pathway in these cells (17). A later work showed that Gene 33
facilitates mammary epithelial cell apoptosis resulting from
EGF deprivation (14). This is accomplished by activating the
protein-tyrosine kinase c-Abl through direct interaction with
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its kinase domain,which subsequently phosphorylates and acti-
vates the p73 tumor suppressor (14). A pro-apoptotic role of
Gene 33has also been reported in pancreatic islet-cells, where
it promotes apoptosis induced by the endoplasmic reticulum
stress and DNA-damaging agents (21, 22). Interestingly, Gene
33 has also been shown to be anti-apoptotic in breast cancer
cells and to have no effect on apoptosis in cortical neurons (23,
24). Moreover, transgenic expression of Gene 33 in mouse car-
diomyocytes does not trigger significant apoptosis (25). Thus,
the effect of Gene 33 on cellular apoptosis appears to be cell
type- and dose-dependent.
Our recent work revealed a novel connection between Gene
33 and the DNA damage response (DDR) (26). We found that
Gene 33 depletion increases DNA damage, chromosome insta-
bility, and cell transformation induced by genotoxic Cr(VI) in
lung epithelial cells (26). In the present study, we investigated
the mechanism underlying this novel observation. We report
herein surprising nuclear and chromatin localization of Gene
33, which is in sharp contrast with the current view that Gene
33 is an exclusively cytoplasmic protein. We provide evidence
that Gene 33 may regulate DDR at the chromatin level. Our
results also provide a spatial explanation on the previously
reported regulation of apoptosis by Gene 33 via the c-Abl/p73
pathway.
Results
Ectopic expression of wild-type but not the Y356Amutant
Gene 33 inhibits EGFR signaling
We constructed an adenoviral vector expressing FLAG-
tagged rat Gene 33 containing the Y356Amutation (equivalent
to Y358A of human Gene 33), a critical residue required for
optimal binding of Gene 33 to EGFR or c-Abl (10, 14). Fig. 1A
illustrates the linear structure of rat Gene 33 with the point
mutation sites relevant to this study indicated. To characterize
the adenoviral vector encoding this Gene 33 mutant, we com-
pared the effect of this vector on A549 lung carcinoma cells
with those of the adenoviral vectors expressing -Gal (as a neg-
ative control) and wild-type Gene 33 (17). As shown in Fig. 1B,
ectopic expression of wild-type Gene 33 (Gene 33) but not the
mutant Gene 33 (Gene 33YA) largely prevented the phosphor-
ylation of ERK induced by EGF, consistent with the inhibitory
role ofGene 33 on theEGFR signaling pathway (8, 9, 14, 17). Fig.
1 (C and D) shows that Gene 33YA had reduced interactions
with EGFR and c-Abl compared with wild-type Gene 33 in co-
immunoprecipitation (co-IP) experiments, in agreement with
the previous findings that the mutated residue is critical for
interaction with EGFR and c-Abl (10, 14).
Gene 33 promotes DDR and apoptosis through largely distinct
mechanisms
Our recent study revealed a potential involvement of Gene
33 in DDR. We found that Gene 33 depletion elevates Cr(VI)-
induced DDR (26). To further determine the effect of Gene 33
on DDR, we examined the effect of ectopic expression of Gene
33 and Gene 33YA on DDR. We observed that adenoviral
vector–mediated overexpression of either Gene 33 or Gene
33YA in bothA549 andBEAS-2B cells significantly elevated the
levels of H2AX and p53 phosphorylation at serine 15 (P-p53),
indicating activation of DDR (Fig. 2, A and B). Strikingly, only
wild-type Gene 33, but not Gene 33YA, strongly induced apo-
ptosis, as indicated by induction of cleaved caspase-3 (Fig. 2, A
and B). These data indicate that ectopically expressed Gene 33
induces apoptosis in anEBD-dependentmanner andDDR in an
EBD-independent fashion. Notably, p53 was equally activated
by Gene 33 and Gene 33YA, suggesting that Gene 33–induced
apoptosis is p53-independent. Note that A549 cells showed a
very low basal P-p53 level, which was significantly elevated by
ectopic expression of Gene 33, whereas BEAS-2B cells had a
Figure 1. Ectopic expression ofwild-typebut not the Y356AmutantGene 33 inhibits EGFR signaling and induces apoptosis. A, linear representation of
rat Gene 33 domain structure highlighting Tyr-356 (Y356) within EBD and Ser-250 (S250) with 14-3-3BD. B, A549 cells growing at 80% confluencewere infected
with adenoviral vectors at 50 MOI under serum starvation for 24 h. Cells were then left untreated or treated with EGF (50 ng/ml) for 10 min before harvesting
for Western blotting using antibodies for phospho-ERK, ERK-2, FLAG, and -actin (as loading control), as indicated. C, HEK293T cells were transfected with the
indicated plasmids and harvested 24 h later for immunoprecipitation with an anti-FLAG antibody. The total lysates and immunoprecipitants were then
subjected to Western blotting with the indicated antibodies on the right. D, BEAS-2B cells were transfected with the FLAG-tagged c-Abl plasmid followed by
infectionwith the indicated adenoviral vectors 24 h after transfection. The cells were then harvested 24 h later for immunoprecipitationwith the anti-Gene 33
antibody. The total lysates and immunoprecipitants were then subjected to Western blotting with an anti-FLAG antibody (to detect both FLAG-Gene 33 and
FLAG-c-Abl) and GAPDH.
Gene 33 in the DNA damage response
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much higher basal level of P-p53, which exhibited limited
increase upon ectopic expression of Gene 33. This discrepancy
was probably a result of the compensatory effect from the pres-
ence of SV40 large T antigen, an inhibitor of p53, in BEAS-2B
cells (27). This observation further supports the notion that
Gene 33 triggers apoptosis with limited involvement of p53 in
these cells.
To exclude the possibility that the effect of Gene 33 on DDR
was a result of the adenoviral vector per se, we ectopically
expressed Gene 33 or Gene 33YA using plasmid DNA in
HEK293T cells by conventional transfection.We observed sim-
ilar effects of Gene 33 and Gene 33YA on H2AX as in A549
and BEAS-2B cells (Fig. 2C). Similar to BEAS-2B cells, the basal
level of P-p53 was high in HEK293T cells and was not appre-
ciably elevated by ectopic expression of either wild-type Gene
33 or Gene 33YA (Fig. 2C). As in BEAS-2B cells, HEK239T cells
also contain SV40 large T antigen.
DDR is mediated by ATM family protein kinases that are
activated upon DNA damage (28). Activation of these kinases
leads to phosphorylation of histone H2AX at the serine 139
position to produce H2AX, a hallmark of DDR, and P-p53 (28,
29). To determine whether DDR triggered by ectopic Gene 33
expression is mediated by ATM/ATR, we treated A549 cells
expressing wild-type Gene 33 or Gene 33YA with caffeine, a
known inhibitor of ATM/ATR (30), before harvesting the cells
forWestern blotting.Our data showed that caffeine largely pre-
vented the increase in P-p53 and H2AX induced by ectopic
expression of either wild-type Gene 33 or Gene 33YA (Fig. 2D),
indicating that DDR elicited by Gene 33 is indeed ATM/ATR-
dependent. We next used KU55933, a specific ATM kinase
inhibitor (31), to repeat the experiment in Fig. 2D. As shown in
Fig. 2 (E and F), KU55933 strongly inhibited DDR induced by
eitherwild-typeGene 33 orGene 33YA.Thus,ATM is probably
the kinase that mediates Gene 33-induced DDR. Note that the
ATM kinase activity, manifested as phosphorylation of its ser-
ine 1981 (28), was elevated by wild-type Gene 33 or Gene 33YA
and dramatically reduced by KU55933 (Fig. 2F).
We have shown previously that Gene 33 depletion by RNAi
leads to elevated DDR in response to Cr(VI) (26). To confirm
this, we used a CRISPR/Cas9-based system to deplete Gene 33
in BEAS-2B cells and examined the effect on DDR. As shown
in Fig. 2G, reduced Gene 33 levels led to increased DDR in
response to Cr(VI) in two CRISPR/Cas9 cell clones compared
with the wild-type clone (Fig. 2G). Note that Gene 33 depletion
Figure 2.Gene33promotesDDRandapoptosis throughdistinctmechanisms.A, A549 cellswere infectedwith the indicated adenoviral vectors at 50MOI.
Cells were harvested 24 or 48 h (as indicated) postinfection forWestern blotting using the indicated antibodies (P-p53, phospho-p53-serine 15; p53, total p53;
H2AX, phospho-histone H2AX at serine 139; H2AX, total H2AX; C-casp3, cleaved caspase-3). B, the experiment was performed as in A using BEAS-2B cells. C,
HEK293T cells were transfectedwith plasmids for empty p-CMV5-FLAG, p-CMV5-FLAG-Gene 33, or p-CMV5-FLAG-Gene 33YA followedby harvesting 48 h later
forWesternblotting todetect theproteins indicatedon the right.D, A549 cellswere infectedwith the indicatedadenoviral vectors at 50MOI andharvested24h
later with orwithout treatmentswith caffeine (10mM) for the last 4 h before harvesting.Western blottingwas then performed to detect the proteins indicated
on the right. E and F, the experiment was performed as in Dwith KU55933 (10M) replacing caffeine. G, two clones of BEAS-2B cell lines (C1 and C2) with gene
33 depletion using the CRISPR/Cas9 system and a control BEAS-2B cell line (W) were either left untreated or treated with 5 M Cr(VI) for 6 h. Cells were then
harvested for Western blotting to detect the indicated proteins.
Gene 33 in the DNA damage response
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elevated the levels of both the basal and Cr(VI)-induced
H2AX, particularly ubiquitinated H2AX (Fig. 2G).
Gene 33 promotes apoptosis via both c-Abl/p73 and EGFR/AKT
pathways
A previous study has shown that Gene 33 is able to interact
and activate non-receptor tyrosine kinase c-Abl, thereby induc-
ing mammary epithelial cell apoptosis resulting from EGFR
inactivation (14). c-Abl promotes apoptosis by phosphorylating
and stabilizing p73, a p53 family tumor suppressor (32, 33). To
testwhether a similarmechanism is involved in the induction of
apoptosis by Gene 33 in lung carcinoma cells, we ectopically
expressed either wild-typeGene 33 orGene 33YAusing adeno-
viral vectors with or without the presence of the specific c-Abl
inhibitor nilotinib (34). We found that wild-type Gene 33 but
not Gene 33YA induced strong phosphorylation of p73 at tyro-
sine 99 (P-p73), a target of c-Abl (35) (Fig. 3A). Phosphorylation
of p73 was accompanied by a significantly increased level of
cleaved PARP1, a commonmarker of apoptosis (Fig. 3A). Inhi-
bition of c-Abl by nilotinib largely prevented p73 phosphoryla-
tion and reduced the level of cleaved PARP1 induced by wild-
type Gene 33 (Fig. 3A). In contrast, Gene 33YA elicited levels of
increase in H2AX (when combining ubiquitinated and non-
ubiquitinated forms) and P-p53 equivalent to those elicited by
Gene 33 without notably elevating the level of P-p73 and
cleaved PARP1. Importantly, although nilotinib could partially
prevent the increase in the H2AX level induced by wild-type
Gene 33, it had limited effect on that induced by Gene 33YA
(Fig. 3A). These data indicate that induction of the DDR by
Gene 33 is mediated by both c-Abl-dependent and c-Abl-inde-
pendent pathways. As expected, wild-type Gene 33 but not
Gene 33YA inhibited EGFR tyrosine phosphorylation, in line
with the previous observations (9, 17). Furthermore, knock-
down of Gene 33 alone with siRNA dramatically reduced the
level of P-p73 (Fig. 3B). These data, combined with those in Fig.
2, demonstrate that Gene 33 promotes apoptosis through a
c-Abl/p73-dependent pathway, whereas it activates DDR via
both c-Abl-dependent and -independent pathways.
Previous work has shown that Gene 33, as an inhibitor of
EGFR, can promote apoptosis by inhibiting the survival path-
way downstream of EGFR in cardiomyocytes (17). To confirm
this in lung epithelial and lung cancer cells, we inhibited EGFR
using AG1478, a specific EGFR kinase inhibitor, in BEAS-2B
and A549 cells. We found that inhibition of the EGFR, mani-
fested as a reduced level of EGFR tyrosine phosphorylation,
significantly elevated the levels of P-p73 and cleaved PARP1
without affecting the levels of H2AX and P-p53 in both cell
types (Fig. 3C). The elevated level of P-p73 upon EGFR inhibi-
tion was probably caused by increased binding of Gene 33
with c-Abl resulting from the reduced EGFR activity, as
described previously (14). Furthermore, EGFR inhibition
reduced the level of P-AKT but not P-ERK (Fig. 3C). These
data suggest that both activation of the p73 pathway and
inhibition of the AKT pathway may contribute to apoptosis
induced by EGFR inhibition. Because Gene 33 is a known
EGFR inhibitor, our data support the notion that Gene 33
promotes apoptosis through both activation of the c-Abl/
p73–mediated pro-apoptotic pathway and inhibition of the
EGFR/AKT–mediated pro-survival pathway. Our data also
Figure 3. Gene 33 promotes apoptosis via both c-Abl/p73 and EGFR/AKT pathways. A, A549 cells were infected with adenoviral vectors at 50 MOI and
treated with DMSO (as vehicle) or Nilotinib (2 M) for 48 h before harvesting for Western blotting to detect the proteins indicated on the right (P-EGFR,
phospho-EGFR; P-p73, phospho-p73; PARP, PARP1). B, A549 cells were transfected with either a scrambled siRNA oligonucleotide (Control oligo) or an siRNA
oligonucleotide for Gene 33. Cells were harvested 48 h later for Western blotting to detect the proteins indicated on the right. C, A549 and BEAS-2B cells were
treated with either DMSO (vehicle) or AG1478 (10 M) for 48 h before harvesting for Western blotting to detect the proteins indicated on the right.
Gene 33 in the DNA damage response
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indicate that inhibition of EGFR alone is not sufficient to
induce DDR in these cells.
Gene 33 is partially localized in the nucleus, is associated with
chromatin, and regulates chromatin localization of c-Abl
The association of Gene 33 with DDR, as indicated by the
present work and a previous study (26), raises the probability
that Gene 33 may have nuclear localization, as most of the
mediators ofDDRare in the nucleus (36). The ability ofGene 33
to interact with c-Abl that phosphorylates p73 also implies
probable nuclear presence of this protein, because, whereas
c-Abl can be both cytoplasmic and nuclear (37), p73 is mainly a
nuclear protein (38). Moreover, Gene 33 does contain a puta-
tive NLS (Fig. 1A). To determine this, we transfected plasmids
encoding FLAG-taggedwild-typeGene 33 and various Gene 33
mutants (Fig. 4A) into BEAS-2B cells followed by a cell fraction-
ation assay to examine the subcellular presence of these Gene
33 mutants. Our results showed that whereas wild-type Gene
33 was mainly located in the cytoplasmic fraction, it could also
be detected in the nuclear and the chromatin fractions (Fig. 4B,
lane 2). The Gene 33 mutant containing a point mutation
on the key serine residue within its 14-3-3 domain (Gene
33(S250A); Figs. 1A and 4A), which prevents its phosphoryla-
tion and its interaction with the adaptor protein 14-3-3 (39),
exhibited a significantly reduced level in the cytoplasmic frac-
tion (Fig. 4B, lane 4). The deletionmutantmissing the C-termi-
nal part ofGene 33 (containing the EBD) but retaining the 14-3-
3BD (Gene 33(1–318); Fig. 4A) showed a dramatically reduced
level in the chromatin fraction (Fig. 4B, lane 5). The deletion
mutant of Gene 33 missing the N-terminal portion of the pro-
Figure 4. Gene 33 is partially localized in the nucleus, is associated with chromatin, and regulates chromatin localization of c-Abl. A, schematic
representation of the Gene 33 mutants used in B–F. B–F, BEAS-2B cells were transfected with the indicated FLAG-tagged Gene 33 mutants. Cell fractionation
was carried out as described under “Experimental procedures.” Proteins in different cellular fractions were subjected to Western blotting with antibodies
indicated at the bottom of each panel (anti-FLAG antibody for FLAG-tagged Gene 33). L, long exposure; S, short exposure; T, total lysate; C, cytoplasmic; N,
nuclear (excluding chromatin); Ch, chromatin. G, A549 cells were infected with adenoviral vectors expressing FLAG-tagged wild-type Gene 33 or Gene 33YA.
Cell fractionation was carried out as described under “Experimental procedures” 24 h later. Proteins in the cellular fractions were subjected to Western
blotting to detect proteins indicated on the right. H, cell fractionation was carried out in BEAS-2B cells. Proteins in the cellular fractions were subjected
to Western blotting to detect the proteins indicated on the right. I, A549 cells were infected with adenoviral vectors expressing FLAG-tagged wild-type
Gene 33 for 24 h. Cells were treated with either DMSO (D) or 2.5M Chk1 inhibitor SB218078 (S) for 4 h before harvest. Cell fractionation was then carried
out as described under “Experimental procedures.” Proteins in cellular fractions were subjected to Western blotting to detect proteins indicated on the
right. J, HEK293T cells were transfected with the indicated FLAG-tagged Gene 33 constructs followed by immunoprecipitation with an anti-Gene 33
antibody 24 h later. The products of immunoprecipitation and total cell lysates were then subjected toWestern blottingwith anti-Gene 33 or anti-14-3-3
antibodies as indicated.
Gene 33 in the DNA damage response
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tein but retaining the EBD and the 14-3-3BD (Gene 33(219–
459)) had a subcellular distribution similar to that of wild-type
Gene 33 (Fig. 4B, last lane).
Because we were unable to detect the expression of Gene
33YAmutant (Gene 33YA) using the anti-FLAG antibody (as a
result of the low expression level of this mutant in BEAS-2B
cells) (Fig. 4B, lane 3), we used the anti-Gene 33 antibody (with
a higher sensitivity toward FLAG-tagged Gene 33 than that of
the anti-FLAGantibody) to detect thismutant. As shown in Fig.
4C, we were able to detect Gene 33YA, albeit at a much lower
level as comparedwithwild-typeGene 33.Of note, the detected
Gene 33YA is not endogenous Gene 33, as it did not appear in
the control group (Fig. 4C, lane 1). Notably, Gene 33YAappears
to have proportionally less presence in the chromatin fraction
(Fig. 4C). This result suggests that EBD may be important for
chromatin association of Gene 33, in agreement with the distri-
bution of Gene 33(1–318). Fig. 4 (D–F) shows the quality of the
cell fractionation as indicated by the presence or absence of
GAPDH, a mainly cytosolic protein; PARP1, a mostly nuclear
protein and chromatin-binding protein; and histone H2AX
(H2AX), an exclusive chromatin-associated protein. It is also
noteworthy that the putative NLS located at the very C termi-
nus of Gene 33 (Figs. 1A and 4A) does not seem to be important
for the nuclear localization of Gene 33, as Gene 33(1–318),
which is devoid of theNLS (Fig. 4A), had a rather robust nuclear
presence (Fig. 4B).
We next examined whether nuclear and chromatin localiza-
tion of ectopically expressed Gene 33 also occurs in A549 cells.
We ectopically expressed wild-type Gene 33 and Gene 33YA
using adenoviral vectors in A549 cells and then performed the
cell fractionation assay. As shown in Fig. 4G, these two proteins
all appeared in the nuclear and chromatin fractions. Notably,
most of wild-type Gene 33 was in the chromatin fraction as
comparedwithmuchmore ofGene 33YA in the soluble nuclear
fraction (Fig. 4G, lanes 5–8), despite the fact that the levels of
these two proteins were similar in both total lysates and cyto-
plasmic fractions (Fig. 4G, lanes 1–4). This observation agrees
with the data from BEAS-2B cells, where Gene 33YA and Gene
33(1–318) both had an impaired EBD domain and had much
lower levels in the chromatin fraction than in the nuclear frac-
tion comparedwithwild-typeGene 33. These data confirm that
the EBDmotif of Gene 33 is important for its chromatin target-
ing. Note that significant cleavage of PARP1 occurred in cells
expressing wild-type Gene 33 but not Gene 33YA (Fig. 4G, lane
5), confirming that only wild-type Gene 33 induces significant
apoptosis. Interestingly, a much higher level of c-Abl was
observed in the chromatin fraction of the cells expressing wild-
type Gene 33 than in those expressing Gene 33YA (Fig. 4G,
lanes 7 and 8), suggesting that Gene 33may regulate the target-
ing of c-Abl to the chromatin via its EBD. A cell fractionation
experiment in BEAS-2B cells confirmed that the endogenous
Gene 33 could also be detected in the nuclear and the chroma-
tin fractions using both the anti-Gene 33 antibody and a com-
mercial anti-Mig6 antibody (Fig. 4H).
Binding to 14-3-3 through phosphorylated 14-3-3BD is a
common mechanism for many proteins to maintain cytoplas-
mic localization (40). It has been reported that the key serine
residue (serine 250; Fig. 1A) within the 14-3-3BD of Gene 33
can be phosphorylated by the serine/threonine kinase Chk1
(39, 41). To determine the role of Chk1 in subcellular distribu-
tion of Gene 33, we checked the effect of SB218078, a specific
Chk1 inhibitor. We found that inhibition of Chk1 in A549 cells
led to a significant increase of ectopically expressed Gene 33 in
the chromatin fraction (Fig. 4I).When the nuclear and chroma-
tin fractions were combined, the total nuclear Gene 33 was still
higher in the group with the Chk1 inhibitor (Fig. 4I, compare
the last two lanes). These data indicate that phosphorylation of
Gene 33 by Chk1 probably reduces its nuclear translocation.
Note that the Chk1 inhibitor-treated group showed a higher
level of H2AX, consistent with the previous observation that
Chk1 inhibition increases the level of H2AX as a result of
increase in replicative DNA damage (42). Our co-IP experi-
ment confirmed that ectopically expressed Gene 33S250A
mutant was not able to bind to ectopically expressed 14-3-3
(Fig. 4J).
To further demonstrate the nuclear presence of Gene 33, we
transfected FLAG-tagged Gene 33 into BEAS-2B cells and
examined the subcellular localization of the ectopically ex-
pressed Gene 33 using confocal microscopy after immunofluo-
rescent staining with an anti-FLAG antibody. As shown in Fig.
5A, although the majority of FLAG signals were detected in the
cytoplasm of cells, they were also detectable in the nucleus.
Note that no FLAG signals were detected in the neighboring
cells that did not take up the plasmid. We chose a cell with an
apparently very low level of the nuclear FLAG signal for in-
depth analysis with continuous optical sections. We found that
even in this cell, nuclear FLAG signals were detectable at vari-
ous levels in these sections (Fig. 5B). In another cell with a high
level of the nuclear FLAG signal, strong FLAG signals were
visible in all sections (Fig. 5C).
We next checked the subcellular localization of endogenous
Gene 33 using immunofluorescence confocal imaging with the
anti-Gene 33 antibody. Similar to ectopically expressed Gene
33, the majority of endogenous Gene 33 signals were detected
in the cytoplasm of BEAS-2B cells (Fig. 6A). Continuous optical
sections showed that the Gene 33 signals were detectable in all
sections (Fig. 6B). Taken together, our data demonstrate that
Gene 33 is partially localized in the nucleus, the 14-3-3BD reg-
ulates the nuclear localization ofGene 33, the EBD regulates the
chromatin localization of Gene 33 and c-Abl, and the putative
NLS is not important for the nuclear localization of Gene 33.
Gene 33 binds to histone H2AX and promotes interaction
between ATM and histone H2AX
To investigate the mechanism underlying the activation of
DDRbyGene 33, we surveyed a number of components ofDDR
and repair machinery using co-IP in BEAS-2B cells. We found
that both wild-type Gene 33 and Gene 33YA strongly interact
with histoneH2AX (Fig. 7A). These data are consistentwith the
observation that Gene 33 is associated with the chromatin frac-
tion of the cells and implies that Gene 33 may directly interact
with the DNA damage and repair apparatus.
Given that Gene 33 promotes DDR in an ATM-dependent
fashion, that Gene 33 appears to elevate the activity of ATM,
and that Gene 33 interacts with histone H2AX (Figs. 2 (D–F)
and 7A), we asked whether Gene 33 could interact with ATM
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Figure5.Confocal images showingnuclear localizationofectopically expressedGene33.BEAS-2B cellswere transfectedwith theplasmid containing the
FLAG-taggedGene33 and subjected to confocal imaging asdescribedunder “Experimental procedures.”A, confocal images showing three continuousoptical
sections. B and C, confocal images showing six continuous optical sections of two individual cells.
Figure 6. Confocal images showing nuclear localization of endogenous Gene 33. BEAS-2B cells were cultured on 2-well chamber slides and subjected to
confocal imaging as described under “Experimental procedures.” A, confocal images showing endogenous Gene 33. B, confocal images showing six continu-
ous optical sections.
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and/or affect the interaction between ATMand histoneH2AX.
We co-transfected His-tagged ATM plasmid along with either
the FLAG-tagged wild-type Gene 33 or Gene 33YA plasmids in
HEK293T cells, followed by His pulldown with Ni-NTA resins
under native conditions. As shown in Fig. 7B, both wild-type
Gene 33 andGene 33YA dramatically enhanced the interaction
betweenHis-ATM and histone H2AX. Note that very little his-
tone H2AX was pulled down from cells expressing Gene 33 or
Gene 33YA alone or His-ATM alone (Fig. 7B, lanes 1–3 from
the left), suggesting that the observed effect of Gene 33 on
ATM–histone H2AX interaction was specific. Interestingly,
His pulldown did not show proportional increase of Gene 33
with ATM and histone H2AX (Fig. 7B, third panel from the
bottom). In addition, we were unable to detect direct interac-
tion between ATM andGene 33 in IP experiments with endog-
enous proteins using the anti-Gene 33 antibody or ectopically
expressed FLAG-tagged Gene 33 using an anti-FLAG antibody
(data not shown). These results suggest that whereas Gene 33
promotes the interaction between ATM and histone H2AX, it
may not act by directly bridging the interaction of these two
proteins. It is also possible that the interaction betweenGene 33
and ATM is transient or too weak to be detected under our
experimental conditions.
We next asked whether nuclear localization of Gene 33 is
regulated in response to the genotoxic stress. We carried out
the cell fractionation assay using BEAS-2B cells with or without
treatment with Cr(VI), a known genotoxic agent. As indicated
in Fig. 7C, Cr(VI) treatment for 6 h led to a significant increase
of Gene 33 in the nuclear fraction. Note that Cr(VI) treatment
led to an increased level of H2AX. Intriguingly, however, the
chromatin fraction of Gene 33 was not elevated by Cr(VI).
Nonetheless, these data indicate that a fraction of Gene 33 is
able to translocate to the nucleus upon Cr(VI) treatment.
We noticed that endogenous Gene 33 in the nuclear and
chromatin fractions migrated slightly faster than that in the
cytoplasmic fraction and the total lysate (Figs. 4H and 7C). A
closer examination revealed that faster-migrating Gene 33 also
exists in the total lysate but not in the cytoplasmic faction (Fig.
7C, compare lanes 1 and 2 with lanes 3 and 4). The faster-
migrating fraction could be the Gene 33 protein that is not
phosphorylated at Ser-250. This would be consistent with the
notion that phosphorylation of this residue located in the 14-3-
3BD promotes the binding of Gene 33 to 14-3-3, thereby pre-
venting it from entering the nucleus. Alternatively, the short
form of Gene 33, which has a deletion of 75 amino acids as a
result of alternative splicing (9), may be preferably located in
the nucleus. Of note, this deleted portion of Gene 33 does not
contain any key domains shown in Fig. 1A (9).
Gene 33 overexpression does not induce DNA damage
The increased interaction between ATM and H2AX as well
as the elevated level of DDR after ectopic expression of Gene 33
could be caused by an increase in DNA damage as a result of
replicative or genotoxic stresses (43). Alternatively, Gene 33
may elevate DDR without eliciting DNA damage. Previous
work showed that ectopic expression of the components of
DDR/DNA repair machinery is able to induce DDR in the
absence of DNA damage (44). To determine this, we examined
whether ectopic expression of Gene 33 could induce actual
DNA damage (rather than DDR measured by the level of
H2AX, a surrogate of DNA damage) in A549 cells using the
comet assay. As shown in Fig. 8, neither wild-type Gene 33 nor
Figure7.Gene33 interactswithhistoneH2AXandpromotes interactionbetweenATMandhistoneH2AX.A, BEAS-2Bcellswere infectedwithadenoviral
vectors expressing -Gal, FLAG-tagged Gene 33YA, or FLAG-tagged Gene 33. Cells were harvested 24 h later for immunoprecipitation with an anti-FLAG
antibody. The total lysates and immunoprecipitants were then subjected toWestern blottingwith the indicated antibodies on the right. B, HEK293T cells were
transfected with expression plasmids encoding either FLAG-tagged wild-type Gene 33 or Gene 33YA with or without the presence of His-tagged ATM and
harvested 48 h later for the His-pulldown assay with Ni-NTA resins as described under “Experimental procedures.” The total lysates and His-pulldown proteins
were then subjected toWestern blotting to detect the proteins indicated on the right. C, the cell fractionation assay was performedwith BEAS-2B cells with or
without treatment with 5 M sodium chromate (Na2CrO4) for 6 h.
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Gene 33YA induced significant DNA damage 24 h after ectopic
expression in A549 cells, manifested as an inability of these
proteins to increase comet formation. These data indicate that
rather than triggering DDR by inducing DNA damage, Gene 33
promotes DDR without causing DNA damage.
Discussion
The data presented herein support the following conclu-
sions. 1) Ectopic expression of Gene 33 triggers DDR in an
ATM-dependent fashion and in both c-Abl–dependent and
–independent manners in lung epithelial cells and lung cancer
cells. 2) Gene 33 promotes apoptosis through both the c-Abl/
p73 and the EGFR/AKT pathways in lung epithelial cells and
lung cancer cells. 3) Gene 33 is partially located in the nucleus
and associated with chromatin. 4) An intact EBDmotif of Gene
33 is required for Gene 33 to induce apoptosis and is important
for Gene 33 to target c-Abl to chromatin. 5) Binding to 14-3-3
through its 14-3-3BD prevents Gene 33 from entering the
nucleus. 6) Gene 33 interacts with histone H2AX and enhances
ATM–histoneH2AX interaction, thereby elevatingDDRwith-
out causing DNA damage. To our knowledge, this is the first
report on the nuclear localization and function of Gene 33.
These findings are in contrast to the current view that Gene 33
is an exclusively cytoplasmic protein that performs its functions
by interacting with other cytoplasmic proteins.
The 14-3-3BD of Gene 33 is clearly important for its nuclear
translocation, as a point mutation at the key serine residue
(S250A) within the 14-3-3BD dramatically reduced the cyto-
plasmic level and enhanced the nuclear presence of Gene 33
(Fig. 4B). This residue has been shown to be a target of Chk1
(39, 41), a protein kinase involved in cell cycle check point con-
trol in response to replicative DNA damage. However, Gene 33
is believed to be phosphorylated by cytoplasmic fraction of
Chk1, thereby enhancing its stability by binding to 14-3-3 (39,
41). Our results suggest that binding to 14-3-3 probably pre-
vents Gene 33 from entering the nucleus and show that Chk1
could indeed affectGene 33nuclear translocation by phosphor-
ylating its 14-3-3BD (Fig. 4). It is surprising that the putative
NLS of Gene 33 appears to be unimportant for its nuclear local-
ization. A similar phenomenon also exists with the tumor
suppressor PTEN. Although lacking a classic NLS, its nuclear
translocation is mediated by mechanisms such as simple dif-
fusion, active shuttling, and monoubiquitination-dependent
nuclear import (45–47). It is conceivable that Gene 33 may
enter the nucleus in a similar fashion.
It is interesting that the EBD motif of Gene 33 appears to
regulate its chromatin association, as this is also the critical
domain for its interaction with EGFR and c-Abl (8–10, 14).
Our data also show that the EBD helps target c-Abl to chro-
matin, as a higher level of ectopically expressed wild-type
Gene 33 in chromatin was accompanied by a significantly
elevated level of c-Abl at chromatin compared with Gene
33YA (Fig. 4G). This mechanism is probably responsible for
the c-Abl-dependent activation of DDR and apoptosis by
Gene 33 discussed below.
Figure 8. Ectopic Gene 33 expression does not trigger DNA damage. A549 cells were either untreated (Control) or treated with UV for 30 s and then
recovered for 2 h (UV) or infected with the indicated adenoviral vectors at 50 MOI for 24 h. Cells were then used to detect DNA damage by the comet assay as
described under “Experimental procedures.” A–E, representative images of the comet assay. F, the DNA damage index (percentage of DNA in the tail) was
determined using OpenComet comet assay software (mean S.D. (error bars); *, p 0.05).
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The finding that ectopic Gene 33 expression activates DDR
confirms the involvement of Gene 33 in DDR proposed in our
recent publication (26), in which we reported that Gene 33 reg-
ulates Cr(VI)-induced DNA damage. The nuclear and chroma-
tin localization of Gene 33 described herein provides a spatial
explanation for the regulation of DDR by Gene 33, as most of
the molecular processes mediating these activities occur in the
nucleus. The findings that Gene 33 activates DDR in an ATM-
dependent fashion and by promoting interaction between his-
tone H2AX and ATM logically explain why overexpression of
Gene 33 triggers DDR. The enhanced interaction between
ATM and histone H2AX should promote phosphorylation of
histone H2AX by ATM. However, the apparent lack of signifi-
cant direct interaction between Gene 33 and ATM suggests
that Gene 33may not bridge the interaction between ATM and
H2AXor activateATMdirectly. It has been reported that initial
ATM activation after DNA damage induced by -irradiation is
a result of ATM autophosphorylation induced by perturbation
of the chromatin structure (48). Given our findings that Gene
33 is localized at chromatin and induces DDR without causing
DNA damage, it is conceivable that Gene 33 may activate DDR
by altering the chromatin structure.
Previous studies have showed that forced targeting of indi-
vidual components of DNA repair machinery (such as NBS1,
MRE11, MDC1, and ATM) is sufficient to activate DDR with-
out DNA damage (44). These findings support an intriguing
possibility that Gene 33may participate directly in DNA repair.
This model would explain our previous observation that deple-
tion of the endogenous Gene 33 also increases DDR and elevate
DNA damage induced by genotoxic agents (26). An attractive
model would be that Gene 33 overexpression induces DDR
(without causing DNA damage), probably by perturbing the
chromatin structure, whereas Gene 33 depletion may exacer-
bate DNA damage, induced by genotoxic agents in particular,
by weakening DDR, thereby compromising DNA repair. Bio-
logically, reduced Gene 33 expression as a result of mutation,
deletion, or expression suppressionmay lead to increasedDNA
damage, genomic instability, and tumorigenesis. This model
would be consistent with the tumor-suppressing function of
Gene 33.We have shown that Cr(VI) suppresses the expression
level of Gene 33 in lung epithelial and lung cancer cells (26). It is
conceivable that lowered Gene 33 expression as a result of
exposure to Cr(VI) (or other carcinogens) may contribute to
tumorigenesis via these mechanisms.
We observed that ectopically expressed Gene 33 induces
DDR through both c-Abl–dependent and –independent path-
ways (Fig. 3A). The dependence on c-Abl apparently requires
EBD of Gene 33. This result is logical, as c-Abl can interact with
and be activated by Gene 33 via the EBD (14). Our finding that
both wild-type Gene 33 and Gene 33YA enhances ATM–
histone H2AX interaction suggests that this is probably the
mechanism underlying the c-Abl–independent activation of
DDR. The c-Abl (or EBD)–dependent activation of DDR was
unlikely to be a result of inhibition of the canonical EGFR sig-
naling pathway by the intact EBD, as inhibition of EGFR did not
affect DDR in these cells (Fig. 3C). Given that c-Abl is an active
participant of DDR andDNA repair (37, 49–52), a more logical
explanationwould be that EBDofGene 33 facilitates chromatin
localization of c-Abl, thereby promoting DDR. Of note, c-Abl
has been shown to be required for proper activation of ATM
and for the early stage of DNA double strand break repair (37,
49). However, given that Gene 33YA often induces H2AX at
an equivalent magnitude as does wild-type Gene 33 (Fig. 2), the
c-Abl-independent pathway is probably the dominant mecha-
nism for induction of DDR byGene 33. Given the complexity of
the DDR and the multifunctional nature of Gene 33, the com-
bined signaling outcome of these two pathways is likely very
complex.
Previous studies in different cell types have reported both
pro-apoptotic and anti-apoptotic functions of Gene 33 (14, 17,
21–23, 39). Gene 33 has also been shown to have no effect on
apoptosis in other studies (24). These results indicate that Gene
33 affects apoptosis in a cell type–dependentmanner.We have
also observed that whether Gene 33 can induce apoptosis upon
ectopic expression is cell type–dependent.4 This cell type–de-
pendent role of Gene 33 in apoptosis is probably due to the fact
that Gene 33 is an adaptor protein with multiple binding part-
ners, including EGFR, CDC42, Grb2, c-Abl, 14-3-3, and NF-B
(8, 9, 14, 16, 39, 41, 53). The interaction of Gene 33 with these
proteins can generate either pro- or anti-apoptotic signals. For
example, Gene 33 has been shown to activate NF-B (53), a
known anti-apoptotic transcription factor (54), whereas inhibi-
tion of EGFR or activation of c-Abl by Gene 33 is pro-apoptotic
(14, 17). Because of the potentially complex interactions with
multiple cellular processes, the eventual biological outcome of
Gene 33 expressionmay depend on the level ofGene 33 expres-
sion, the molecular environment of a particular cell type,
and/or the physiological states of the cell. It is also important to
stress that Gene 33 typically induces significant apoptosis when
overexpressed. There is no evidence so far that Gene 33 is a
component of the apoptotic machinery per se. Thus, the effect
of Gene 33 on apoptosis is probably indirect, by altering the
balance between survival and death signals in the cell.
At the molecular level, our data in BEAS-2B and A549 cells
support the previous findings in mammary epithelial cells that
Gene 33 facilitates apoptosis by binding to and activating c-Abl,
thereby elevating apoptosis through the c-Abl/p73 pathway
(14). Our finding that pharmacological inhibition of EGFR was
sufficient to suppress AKT activity supports the notion that
inhibition of the AKT-mediated survival pathway also contrib-
utes to Gene 33–induced apoptosis in these cells, as Gene 33 is
a well-established inhibitor of EGFR (10). This result is consis-
tent with our previous report that Gene 33 promotes apoptosis
by inhibiting EGF-induced activation of AKT (17). Thus, the
AKT survival pathway, in concert with the c-Abl/p73 pathway,
mediates apoptosis induced by Gene 33 overexpression in lung
epithelial and lung cancer cells.
Gene 33 is regarded as a tumor suppressor protein in the lung
and has been implicated in lung epithelial cell transformation
induced by Cr(VI) (26, 55). The obvious connection of Gene 33
with EGFR signaling has led tomuch research effort devoted to
determining howGene 33 regulates EGFR-mediated cell trans-
formation, tumor progression, and drug resistance. Research
4 C. Li, S. Park, X. Zhang, and D. Xu, unpublished observations.
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on how Gene 33 may mediate early cellular events that lead to
cell transformation, especially induced by genotoxic environ-
mental carcinogens such as Cr(VI), is lacking. The involvement
of Gene 33 inDDR, revealed in this and our previous study (26),
provides novel insights into how this protein may modulate
carcinogenesis. Future investigation in this direction is clearly
warranted. Fig. 9 outlines the proposed signaling model based
on the current and previous studies.
Experimental procedures
Cell lines and cell culture
BEAS-2B human bronchial epithelial cells, A549 human lung
adenocarcinoma cells, and HEK293T cells were obtained from
American Type Culture Collection. Cells were cultured in
DMEM supplemented with 10% FBS and antibiotics (100
units/ml of penicillin and 100 g/ml of streptomycin sulfate)
under 5% CO2 conditions. Cells were maintained by passing
before they reached confluence (every 2–4 days) unless cell
treatments required longer culture time before harvesting for
analyses, as indicated in the figures.
Antibodies, plasmids, adenoviral vectors, and chemicals
The antibody to Gene 33 has been described previously (9,
17). The antibody to H2AX was purchased from Biolegend.
Antibodies toGAPDH, EGFR,Mig6, and-actinwere obtained
from Santa Cruz Biotechnology, Inc. The antibody to M2-
FLAG was purchased from Sigma-Aldrich. The antibody to
P-p73 (Tyr-99) was purchased from Abcam. Antibodies to
P-p53 (Ser-15), p53, P-ATM (Ser-1981), ATM, H2AX, cleaved
caspase-3, PARP1, P-ERK, ERK2, P-AKT, AKT, p73, PY-100,
pan-14-3-3, -tubulin, and c-Abl were purchased from Cell
Signaling Technology.
The mammalian expression plasmids encoding FLAG-
tagged rat Gene 33 and its deletion mutants have been
described previously (9). A tyrosine to alanine point mutation
was made at residue 356 of rat Gene 33 to create the FLAG-
tagged rat Gene 33Y356A (Gene 33YA) mutant. A serine to
alanine point mutation was made at residue 250 of rat Gene
33 to create the FLAG-tagged rat Gene 33S250A (Gene
33S250A) mutant. Point mutations were constructed using a
PCR-based approach and confirmed by Sanger sequencing.
The mammalian expression vector for EGFR has been
described previously (9). pcDNA3-Abl-His6-FLAG was a gift
from Benjamin Turk (Addgene plasmid 52684). pcDNA3.1()
FLAG-His-ATM WT was a gift from Michael Kastan (Add-
gene plasmid 31985).
Adenoviral vectors encoding -Gal and Gene 33 have been
described previously (9). Adenoviral vector encoding Gene
33YAwas constructed usingGene 33Y356Amutant cDNA and
the same method for the Gene 33 adenoviral vector (9).
The EGFR inhibitor AG1478 was purchased from Cayman
Chemical. The c-Abl inhibitor nilotinib was purchased from
AdipoGen. Caffeine was purchased from Sigma-Aldrich. The
ATM kinase inhibitor KU-55933 was purchased from Milli-
pore. The Chk1 inhibitor SB218078was purchased fromTocris
Bioscience.
CRISPR/Cas9–mediated Gene 33 depletion
A double-stranded single-guide RNA oligonucleotide (5-
CACCGCAGTCTGAACTCTTCTGCTC-3/5AAACGAGC-
AGAAGAGTTCAGACTGC-3) was cloned into pX330 vector
(Addgene) and transfected to BEAS-2B cells alongwith a vector
expressing GFP (pcDNA3-GFP, at one-tenth of the amount of
pX330). Transfected cells expressing high levels of GFP (top
3%) were isolated and seeded individually to 96-well plates 24 h
post-transfection using FACS. After clonal expansion, the
expression levels of Gene 33 in cell clones were determined
using Western blotting. Clones with a dramatically reduced
level of Gene 33 were selected and tested for indel formation
using the T7E1 assay according to the standard procedure and
the primer pair 5-GAGCCATGGGGAATATGAGG-3/5-
GAAGATCCCACGTCCATGAA-3. The same procedure was
carried out using the empty pX330 vector for the WT clones.
Western blotting
A standard Western blotting procedure was using through-
out the study. SDS-PAGE was carried out using the minigel
system from Bio-Rad after harvesting cells with 1 sample
buffer. Proteins in gels were then blotted to PVDF membrane.
After blocking with TBST containing 5% nonfat dry milk, the
membrane was incubated overnight with primary antibodies
diluted with TBST containing 5% BSA using dilutions sug-
gested by themanufacturers. After a thoroughwashwithTBST,
the membrane was further incubated with horseradish peroxi-
dase-conjugated secondary antibodies for 1 h at room temper-
ature followed by thorough washing with TBST buffer. The
signals were developed with an ECL system (Pierce) and
detected with X-ray film.
Figure 9. Proposed functions of Gene 33 in DDR and apoptosis. Nuclear
Gene 33 activates DDR via both EBD-dependent and EBD-independent path-
ways by directly activating c-Abl and promoting the interaction between
ATM and histone H2AX, respectively. Both pathways are dependent on ATM.
Activation of c-Abl by Gene 33 also induces apoptosis in a p73-dependent
pathway. Gene 33 promotes apoptosis also by inhibiting EGFR and AKT-me-
diated pro-survival pathway. Both of these pathways are dependent the EBD
motif of Gene 33. C, cytoplasm; N, nucleus.
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Immunoprecipitation
Cells were lysed in the radioimmune precipitation assay
buffer supplemented with a mixture of proteases and phospha-
tase inhibitors. The lysates were then centrifuged for 30 min at
10,000 g. The supernatantswere kept as total cell lysates. One
g of the antibody and 40 l of protein G-agarose resin
(Upstate Biotechnology, Inc.) were then added to 1 mg of each
cell lysate and incubated at 4 °C overnight, followed by exten-
sive washing with the lysis buffer. Proteins bound to the resin
were then extracted with 5 SDS sample buffer and subjected
to SDS-PAGE followed by Western blotting with appropriate
antibodies.
His-pulldown assay
Cells were lysed in the radioimmune precipitation assay
buffer supplemented with proteases and phosphatase inhibi-
tors. The lysates were then centrifuged for 30min at 10,000 g.
The supernatants were kept as total cell lysates. 40 l of Ni-
NTA resins (ThermoFisher Scientific) were then added to 1mg
of each cell lysate and incubated at 4 °C for 4 h, followed by
extensive washing with the lysis buffer. Proteins bond to the
resin were then extracted with 5 SDS sample buffer and sub-
jected to SDS-PAGE followed byWestern blotting with appro-
priate antibodies.
Cell fractionation assay
Cell fractionation experiments were carried out on ice or at
4 °C throughout. Cells were harvested by trypsinization after
they were washed once with ice-cold PBS followed by centrifu-
gation at 100  g to pellet the cells. Cell pellets were washed
once with ice-cold PBS and resuspended in Buffer H (10 mM
HEPES, pH 7.9, 50 mM NaCl, 0.5 M sucrose, 0.1 mM EDTA,
0.5% Triton X-100, 1 mM DTT, 100 mM NaF, 1 mM sodium
orthovanadate, and protease inhibitors). After centrifugation
for 8 min at 1500  g, supernatants were transferred to fresh
tubes and centrifuged again for 15 min at 14,000  g. The
supernatants after the second centrifugation were kept as cyto-
plasmic fractions. The pellets after the first centrifugation were
washed twice with Buffer A (10mMHEPES, pH 7.9, 10mMKCl,
0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, and protease inhib-
itors) followed by centrifugation for 10 min at 1500  g. After
discarding the supernatants, the pellets were resuspended in
Buffer C (10 mM HEPES, pH 7.9, 500 mM NaCl, 0.1 mM EDTA,
0.1 mM EGTA, 0.1% Nonidet P-40, 1 mM DTT, and protease
inhibitors) followed by extensive vortexing and centrifugation
15 min at 14,000  g. The supernatants were transferred to
fresh tubes as nuclear extracts. The pellets were washed with
Buffer C, followed by centrifugation for 10 min at 14,000  g.
After discarding the supernatant, the pellets were kept as the
chromatin fractions. Forty g of proteins from each fraction
were subjected to SDS-PAGE and Western blotting to detect
the indicated proteins.
Confocal microscopy
Cells were cultured on 2-well chamber slides. Twenty-four h
later, cells were fixed with 1% formaldehyde followed by 70%
ethanol, permeabilized with 0.1% Triton X-100, blocked with
1% BSA, and incubated with either an anti-Gene 33 antibody or
an anti-FLAG antibody followed by FITC-conjugated second-
ary antibody. The slides were embedded in Antifade containing
DAPI. The fluorescent images were captured using a confocal
microscope.
Comet assay
The alkaline version of the comet assaywas performed essen-
tially as described previously (56). Briefly, after treatments,
A549 cells were trypsinized and washed with PBS. Then 4000
cells in 40 l of PBS were mixed with 120 l of low-melting
point agarose in PBS at 37 °C. One hundred ten l of the mix-
ture was then pipetted onto eachwell of the Trevigen COMET-
SLIDE (Trevigen Inc., Helgerman, CT). After 15min at 4 °C for
solidification, the slides were immersed in prechilled lysis solu-
tion (1.2 M NaCl, 100 mMNa2EDTA, 0.1% sodium lauryl sarco-
sinate, 0.26 M NaOH) at 4 °C overnight. The slides were then
rinsed in the electrophoretic buffer (30 mM NaOH, 2 mM
Na2EDTA, pH 12.3) followed by electrophoresis at 10 V for
25 min in electrophoretic buffer at room temperature. After
electrophoresis, the slideswere rinsedwith distilledwater, fixed
with 70% ethanol, and air dried. The slides were then stained
with Vista Green DNA Dye (Cell Biolabs, San Diego, CA).
Images were then acquired using a fluorescence microscope
and analyzed with the OpenComet comet assay software to
calculate the percentage of tail DNA.
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